export interface Guide {
  slug: string
  title: string
  seoTitle: string
  seoDescription: string
  date: string
  excerpt: string
  readTime: string
  body: string
}

export const guides: Guide[] = [
  {
    slug: 'beginners-guide-to-research-peptides',
    title: "Beginner's Guide to Research Peptides",
    seoTitle: "Beginner's Guide to Research Peptides — What They Are, How They Work",
    seoDescription:
      'New to research peptides? Learn what peptides are, how lyophilized peptides work, the difference between GLP, BPC, and copper peptide classes, and how to get started.',
    date: '2026-03-01',
    excerpt:
      'Research peptides explained from first principles: what they are, how lyophilization works, peptide classes, and the compound landscape for new researchers.',
    readTime: '10 min',
    body: `
## What Is a Research Peptide?

A peptide is a short chain of amino acids — the same building blocks that make up proteins. The distinction between a peptide and a protein is generally size: peptides are under 50 amino acids; proteins are larger. Most research peptides are under 20 amino acids, and many are 3–15 AA.

Research peptides are synthetic compounds designed to mimic or modulate specific biological signaling pathways. They are supplied for laboratory research use — studying receptor interactions, cellular mechanisms, and systemic effects in controlled settings.

## Why Synthetic?

Natural peptides are produced by cells and typically have very short half-lives — minutes to hours in physiological conditions. Synthetic analogs incorporate structural modifications that extend stability:

- **DPP-IV resistance:** Amino acid substitutions at position 2 that block dipeptidyl peptidase-IV cleavage (e.g., Teduglutide's Ala²→Gly² substitution)
- **Albumin binding:** Fatty acid side chains that bind albumin, extending plasma half-life from minutes to days (e.g., Semaglutide's C18 diacid modification)
- **N-terminal extensions:** Added amino acid sequences that reduce binding protein affinity (e.g., IGF-1 LR3's 13-AA extension)

These modifications are not random — each addresses a specific stability limitation of the native peptide.

## What Is Lyophilization?

Lyophilization (freeze-drying) is the preservation method used for research peptides. The process:

1. Freeze the peptide solution
2. Apply vacuum to sublimate ice directly to vapor (skipping the liquid phase)
3. The dry solid — the lyophilized cake or powder — retains the peptide in a stable, shelf-stable form

The result is a vial of dry powder that reconstitutes to the original solution when bacteriostatic water is added. Lyophilized peptides are stable at −20°C for 12–24+ months; reconstituted solutions are stable at 2–8°C for up to 4 weeks.

## The Major Research Peptide Classes

### GLP Receptor Agonists
Target glucagon-like peptide receptors in the GI tract, pancreas, and CNS. The class spans mono-receptor (GLP-1 S / Semaglutide), dual-receptor (GLP-2 T / Teduglutide), and tri-receptor (GLP-3 R / Retatrutide) compounds.

### Structural and Repair Peptides
BPC-157, TB-500, and related compounds studied for interactions with tissue repair pathways — NO system, VEGF signaling, actin dynamics.

### Cosmetic Peptides
GHK-Cu and SNAP-8 target skin biology pathways — collagen gene expression and SNARE complex neuromuscular junction signaling respectively.

### GH Axis Peptides
CJC-1295 and Ipamorelin target the growth hormone releasing hormone receptor and ghrelin receptor (GHS-R1a) respectively. IGF-1 LR3 is a downstream GH axis analog.

### Longevity Peptides
Epithalon (telomerase activation research) and NAD+ (sirtuin/PARP substrate) address cellular aging mechanisms.

## Getting Started: What to Know

1. **Purity matters:** Research-grade peptides should carry HPLC purity certification. >98% is the standard for serious research applications. Lower purity introduces impurity variables that confound results.

2. **Reconstitution is required:** All lyophilized peptides need bacteriostatic water before use. Have BW available before ordering peptides.

3. **Storage is simple:** Store lyophilized vials at −20°C long-term. Move to 2–8°C refrigeration once reconstituted.

4. **Test reports:** Quality suppliers provide third-party HPLC test reports. Always verify these are available for any product you source.
    `.trim(),
  },
  {
    slug: 'glp-1-vs-glp-2-vs-glp-3-explained',
    title: 'GLP-1 vs GLP-2 vs GLP-3: The Complete Comparison',
    seoTitle: 'GLP-1 vs GLP-2 vs GLP-3 — Receptor Differences, Mechanisms, Research Compounds',
    seoDescription:
      'Comprehensive comparison of GLP-1, GLP-2, and GLP-3 receptor pathways. Semaglutide vs Teduglutide vs Retatrutide — mechanisms, research outcomes, and protocol applications.',
    date: '2026-03-08',
    excerpt:
      'Three GLP receptor pathways, three distinct mechanisms. Here is the complete breakdown of GLP-1, GLP-2, and GLP-3 biology and how each research compound engages it.',
    readTime: '9 min',
    body: `
## The GLP Family: Three Pathways, One Precursor

GLP-1 and GLP-2 are both derived from proglucagon — the same precursor peptide — through tissue-specific proteolytic processing in intestinal L-cells. GLP-3 is a research designation for Retatrutide's multi-receptor profile, not a distinct endogenous peptide.

Despite sharing a precursor, GLP-1 and GLP-2 have entirely different receptor targets, expression patterns, and physiological functions.

## GLP-1: The Metabolic Regulator

**Receptor:** GLP-1R
**Primary expression:** Pancreatic beta cells, CNS (hypothalamus, brainstem), stomach, lung
**Key effects:** Insulin secretion (glucose-dependent), glucagon suppression, gastric emptying delay, CNS appetite suppression

GLP-1 is released from L-cells in response to nutrient ingestion. Its insulin-stimulating effect is "glucose-dependent" — it only triggers insulin release when blood glucose is elevated, which limits hypoglycemia risk.

The CNS effects of GLP-1R activation are equally important: GLP-1R in the hypothalamic arcuate nucleus and brainstem NTS reduces food intake and increases satiety signaling.

**Research compound:** GLP-1 S (Semaglutide) — a 94% homologous analog with C18 diacid modification for albumin binding (~7-day half-life).

## GLP-2: The Intestinal Trophic Factor

**Receptor:** GLP-2R
**Primary expression:** Intestinal enteroendocrine cells (submucosal neurons, crypt cells)
**Key effects:** Intestinal epithelial proliferation, mucosal surface area expansion, reduced intestinal permeability, enhanced nutrient absorption

GLP-2 has no meaningful metabolic or CNS effects at physiological concentrations — it is almost exclusively an intestinal trophic factor. GLP-2R activation drives crypt cell proliferation (increasing villus height) and inhibits enterocyte apoptosis (reducing cell loss).

The result: expanded intestinal surface area, improved mucosal barrier integrity, and enhanced nutrient absorption capacity.

**Research compound:** GLP-2 T (Teduglutide) — an analog with Ala²→Gly² substitution conferring DPP-IV resistance and ~2× half-life extension vs native GLP-2.

## GLP-3 R: The Triple Agonist

**Receptors:** GLP-1R + GIPR + Glucagon receptor
**Research compound:** Retatrutide (2381089-83-2)

Retatrutide is not a "GLP-3" in any endocrine biology sense — no endogenous GLP-3 exists. The "GLP-3 R" designation reflects its triple-receptor target profile in research shorthand.

The three-receptor mechanism works through synergistic pathway engagement:
- **GLP-1R:** Appetite suppression + glucose-dependent insulin secretion
- **GIPR:** Additional insulin secretion potentiation, possible GLP-1 nausea attenuation
- **GcgR:** Energy expenditure increase through hepatic glucose modulation and thermogenic pathway activation

The GcgR component is the key differentiator from tirzepatide (GLP-1R + GIPR only). Phase 2 data attributed approximately 6–8% additional weight effect to the glucagon axis above tirzepatide's dual-receptor baseline.

## Comparative Research Outcomes

| Compound | Receptors | Peak Phase 2/3 Effect | Trial Duration |
|---|---|---|---|
| GLP-1 S (Semaglutide) | GLP-1R | −14.9% | 68 weeks |
| GLP-2 T (Teduglutide) | GLP-2R | Mucosal (not weight) | 24 weeks |
| GLP-3 R (Retatrutide) | GLP-1R+GIPR+GcgR | −28.7% | 48 weeks |

## Which Belongs in Which Research Design

**Pure metabolic research:** GLP-1 S or GLP-3 R — depending on whether mono or tri-receptor mechanism is the study focus.

**Intestinal mucosal research:** GLP-2 T — the only compound with primary GLP-2R activity.

**Comparative receptor research:** All three — enabling controlled comparison of mono, dual, and triple receptor engagement effects on common outcome markers.

**Full-protocol stack:** GLP-3 R as primary compound, GLP-2 T as gut integrity adjunct.
    `.trim(),
  },
  {
    slug: 'peptide-stack-protocol-design',
    title: 'Designing a Peptide Research Protocol: Layer-by-Layer',
    seoTitle: 'Peptide Protocol Design — How to Build a Multi-Compound Research Stack',
    seoDescription:
      'How to design a layered peptide research protocol. GLP core, gut recovery, skin, lean mass, and longevity layers explained — compound selection rationale and research structure.',
    date: '2026-03-18',
    excerpt:
      'Layer-by-layer protocol design for multi-compound peptide research. Rationale for each layer, compound selection, and how the pathways interact.',
    readTime: '11 min',
    body: `
## The Case for Layered Protocol Design

Single-compound research answers a single mechanistic question. Multi-compound protocol research asks a different kind of question: how do multiple non-overlapping pathways interact when engaged simultaneously?

The 5-layer protocol design addresses this by selecting compounds that cover distinct receptor pathways with minimal mechanism overlap — enabling research that no single compound can support.

## Layer 1: GLP Core

**Primary compound:** GLP-3 R (Retatrutide)
**Mechanism:** Tri-receptor (GLP-1R, GIPR, GcgR)
**Research focus:** Metabolic recomposition — energy balance, appetite regulation, body composition

Retatrutide is the primary study compound because it produces the strongest signal in its class. The Phase 2 −28.7% at 48 weeks is the most compelling single-compound GLP result in current literature.

The GLP core establishes the metabolic research baseline. All other layers are adjunct to this primary axis.

## Layer 2: Gut Recovery

**Compounds:** BPC-157 + GLP-2 T
**Mechanisms:** NO system/VEGFR2 (BPC-157), GLP-2R epithelial trophism (GLP-2 T)
**Research focus:** GI mucosal integrity during GLP-core protocol

The rationale for Layer 2 follows from Layer 1: GLP receptor agonists reduce gastric motility and caloric throughput. Investigating how GI mucosal integrity responds to this environment — and whether it can be supported by gut-targeted compounds — is a natural research extension.

BPC-157 and GLP-2 T address this through complementary, non-overlapping mechanisms. BPC-157 targets the NO system and direct mucosal protection. GLP-2 T targets GLP-2R epithelial proliferation. Using both covers the maximum research breadth for this layer.

## Layer 3: Skin & Glow

**Compounds:** GHK-Cu + SNAP-8
**Mechanisms:** Gene expression/collagen matrix (GHK-Cu), SNARE complex/NMJ (SNAP-8)
**Research focus:** Integumentary tissue response during metabolic recomposition

Body composition changes affect skin tissue — collagen architecture, dermal thickness, and expression line dynamics are all relevant outcome areas in the context of significant body composition shifts.

GHK-Cu (4,000+ gene interactions, primarily collagen/elastin upregulation) and SNAP-8 (SNARE complex interaction for NMJ research) cover the two primary skin research pathways.

## Layer 4: Lean Mass

**Compounds:** CJC-1295/Ipamorelin + IGF-1 LR3
**Mechanisms:** GHRH receptor + GHS-R1a (CJC/Ipa), IGF-1R (IGF-1 LR3)
**Research focus:** GH axis activation during caloric restriction phase

GLP-based protocols reduce caloric intake. In this context, GH axis research asks: how does the somatotropic axis respond, and can GH axis activation support lean mass maintenance during energetic deficit? CJC-1295/Ipamorelin targets pulsatile GH secretion; IGF-1 LR3 addresses downstream GH signaling through the IGF-1 receptor.

## Layer 5: Longevity

**Compounds:** Epithalon + NAD+
**Mechanisms:** Telomerase activation (Epithalon), sirtuin/PARP substrate (NAD+)
**Research focus:** Cellular aging mechanisms during protocol

Epithalon and NAD+ address cellular aging from two angles: telomere biology and cellular energy metabolism. Their mechanism of action is entirely distinct from all other protocol layers — no receptor overlap, no pathway competition.

## Protocol Structure Principles

1. **Non-overlapping mechanisms:** Each layer should target a distinct receptor or pathway family. Mechanism overlap creates confounding variables without additional research benefit.

2. **Hierarchical priority:** The GLP core is primary; all other layers are adjunct. This allows independent analysis of primary vs adjunct compound effects.

3. **Tier your entry:** Not every research design requires all 5 layers simultaneously. Start with Layer 1 (GLP core) and add layers iteratively as research questions expand.

4. **HPLC purity standardization:** Use >98% HPLC purity compounds across all layers. Variable purity across compounds introduces impurity confounders that make multi-compound data harder to interpret.
    `.trim(),
  },
  {
    slug: 'retatrutide-research-guide',
    title: 'Retatrutide: The Triple-Receptor Research Compound',
    seoTitle: 'Retatrutide Research Guide — Triple GLP Agonist Mechanism & Phase 2 Data',
    seoDescription:
      'Retatrutide explained: triple GLP-1R/GIPR/GcgR agonism, Phase 2 NEJM 2023 outcomes, dose-response data, and research protocol placement.',
    date: '2026-03-22',
    excerpt:
      'Retatrutide produces the strongest Phase 2 weight signal in current literature — a breakdown of the receptor architecture, dose-response data, and how researchers stage it.',
    readTime: '8 min',
    body: `
## Why Retatrutide Draws Disproportionate Research Attention

Across published GLP-class compounds, Retatrutide currently produces the highest single-agent weight effect in Phase 2 data — −28.7% at 48 weeks at the top dose. That number is not incremental over the dual-agonist class; it is a meaningful step up that has shifted research attention.

The compound is available as [GLP-3 R 15mg Retatrutide](/products/glp-3-r-15mg) for standard research protocols and in larger formats for extended study designs.

## Triple-Receptor Architecture

Retatrutide engages three receptors simultaneously, each contributing a distinct pathway:

- **GLP-1R:** Hypothalamic appetite suppression, glucose-dependent insulin secretion, gastric emptying delay
- **GIPR:** Potentiates GLP-1R insulin signaling, reduces nausea axis overlap, modulates adipose signaling
- **GcgR:** Hepatic glucose modulation and thermogenic energy expenditure — the axis not present in tirzepatide

The GcgR contribution is what structurally separates Retatrutide from the dual-agonist class. Phase 2 attributed roughly 6–8 percentage points of additional weight effect to the glucagon axis above tirzepatide's baseline.

## Phase 2 Dose-Response Summary

| Weekly Dose | Mean % Weight Change | Duration |
|---|---|---|
| 1mg | −8.7% | 48 wks |
| 4mg | −17.3% | 48 wks |
| 8mg | −22.8% | 48 wks |
| 12mg | −24.2% | 48 wks |
| 24mg | −28.7% | 48 wks |

The curve shows clear dose-dependence without obvious plateau within the studied range.

## How Protocols Typically Stage Retatrutide

Researchers generally follow the trial titration rhythm: begin low, escalate every 4 weeks, and hold at the target dose for the remaining protocol window. Dose escalation is the primary lever for reducing GI tolerability issues during initiation.

## Purchasing and Handling Notes

Research-grade Retatrutide should carry >98% HPLC purity certification with third-party test reports available. The lyophilized powder is stable at −20°C long-term; reconstituted solutions should be held at 2–8°C and used within 28 days.

To start a Retatrutide research protocol, browse [GLP-3 R 15mg Retatrutide](/products/glp-3-r-15mg).
    `.trim(),
  },
  {
    slug: 'tirzepatide-research-guide',
    title: 'Tirzepatide: Dual Incretin Research Compound',
    seoTitle: 'Tirzepatide Research Guide — GLP-1R + GIPR Dual Agonist | SURMOUNT-1',
    seoDescription:
      'Tirzepatide explained: GLP-1R and GIPR co-agonism, SURMOUNT-1 outcomes at −22.5%, titration schedule, and research protocol positioning.',
    date: '2026-03-25',
    excerpt:
      'The dual-incretin research compound behind the SURMOUNT-1 trial. Mechanism, trial data, titration rhythm, and where tirzepatide sits between semaglutide and retatrutide.',
    readTime: '7 min',
    body: `
## Tirzepatide in the Dual-Receptor Tier

Tirzepatide sits between the mono-receptor (Semaglutide) and tri-receptor (Retatrutide) classes. Its GLP-1R + GIPR co-agonism produced −22.5% weight change over 72 weeks in SURMOUNT-1 — a strong signal that validated dual-receptor research as a distinct research direction.

The research-grade compound is available as [GLP-2 T 15mg Tirzepatide](/products/glp-2-t-15mg) at the SURMOUNT-1 maintenance dose.

## How GLP-1R and GIPR Combine

The dual-receptor mechanism is additive rather than redundant:

- **GLP-1R:** Appetite suppression and glucose-dependent insulinotropic effect
- **GIPR:** Potentiates insulin secretion and attenuates the GLP-1 nausea signaling axis
- **Combined:** Greater insulinotropic response and improved tolerability vs mono-agonist GLP-1R

Research suggests GIPR's role in nausea attenuation explains part of why dual-agonists are typically tolerated at higher effective GLP-1R activation.

## SURMOUNT-1 Dose-Response at a Glance

- 5mg maintenance: −15.0% at 72 wks
- 10mg maintenance: −19.5%
- 15mg maintenance: −22.5%

All three doses showed dose-dependence with a relatively linear response — useful for dose-comparison research.

## Titration Rhythm Matching Trial Design

The SURMOUNT-1 titration:

1. Weeks 1–4: 2.5mg (initiation)
2. Weeks 5–8: 5mg
3. Weeks 9–12: 7.5mg
4. Weeks 13–16: 10mg
5. Weeks 17+: 15mg (target maintenance)

Most research protocols follow this rhythm exactly, since it is the best-characterized tolerability curve in the literature.

## Research Contexts Tirzepatide Addresses

- **Dual vs mono comparison research** — alongside semaglutide for side-by-side receptor comparisons
- **Dual vs triple comparison research** — alongside retatrutide to isolate the GcgR contribution
- **Glycemic research** — where the GIPR axis adds beyond pure GLP-1R action

## Sourcing for Extended Protocols

The SURMOUNT-1 design runs 72 weeks. For multi-month research, bulk formats or multi-vial packs reduce resupply risk. See [GLP-2 T 15mg Tirzepatide](/products/glp-2-t-15mg) for the single-vial option.
    `.trim(),
  },
  {
    slug: 'semaglutide-research-guide',
    title: 'Semaglutide: The Mono-Receptor GLP-1 Reference',
    seoTitle: 'Semaglutide Research Guide — GLP-1R Agonist | STEP-1 & Half-Life',
    seoDescription:
      'Semaglutide explained: C18 fatty acid modification, STEP-1 outcomes, 7-day half-life, and research positioning as the GLP-1R reference compound.',
    date: '2026-03-28',
    excerpt:
      'Semaglutide is the mono-receptor GLP-1 reference compound — the baseline every dual and triple agonist is measured against. Here is why.',
    readTime: '7 min',
    body: `
## The Reference Compound for GLP Research

When new GLP-class compounds are published, their effect size is almost always reported relative to semaglutide. That makes semaglutide the practical reference point for the entire class — and the starting point for most receptor-comparison research.

For comparison studies, [GLP-1 S 10mg Semaglutide](/products/glp-1-s-10mg) is the standard research format.

## The C18 Fatty Acid Modification

Native GLP-1 has a half-life measured in minutes. Semaglutide extends this to approximately 7 days through a C18 fatty diacid side chain attached via a short linker. The fatty acid binds circulating albumin, which:

1. Shields the peptide from DPP-IV cleavage
2. Reduces renal clearance
3. Provides a long-lived albumin-peptide complex that slowly releases active compound

The result is a research compound with once-weekly dosing kinetics — which in turn shapes protocol design.

## STEP-1 Summary

The STEP-1 trial (NEJM 2021):

- **Duration:** 68 weeks
- **Dose:** 2.4mg/week maintenance
- **Mean weight change:** −14.9%
- **Placebo-adjusted:** −12.4 percentage points

This result established semaglutide as the effective ceiling for mono-receptor GLP-1R research until dual- and triple-receptor compounds extended the ceiling further.

## Research Positioning

Semaglutide earns its research utility specifically through its mono-receptor profile — not despite it:

- Single-variable receptor research requires single-receptor engagement
- Dose-response studies at GLP-1R benefit from a compound with minimal off-target activity
- Comparative research against dual/triple agonists requires a validated mono-agonist baseline

## Handling and Stability

Lyophilized semaglutide is stable at −20°C for 12+ months. Reconstituted solution at 2–8°C is typically used within 28 days. All research-grade semaglutide should carry >98% HPLC certification.

## Research Window Design

Semaglutide's 7-day half-life means weekly dosing is protocol-native. Steady state is reached at approximately 4–5 weeks, so research windows need to account for this ramp-up period. Most protocols discard the first 4–6 weeks from primary analysis for this reason.

Start a semaglutide research protocol at [GLP-1 S 10mg Semaglutide](/products/glp-1-s-10mg).
    `.trim(),
  },
  {
    slug: 'bpc-157-research-guide',
    title: 'BPC-157: Pentadecapeptide Research Overview',
    seoTitle: 'BPC-157 Research Guide — Sikiric Literature, NO System, VEGFR2',
    seoDescription:
      'BPC-157 research background: the Sikiric laboratory literature, pentadecapeptide structure, nitric oxide and VEGFR2 signaling, and research protocols.',
    date: '2026-04-01',
    excerpt:
      'BPC-157 is one of the most-studied research peptides outside the GLP class. A grounded look at the Sikiric literature, the mechanism, and the tissue systems researched.',
    readTime: '9 min',
    body: `
## A Compound Defined by a Single Research Lab

BPC-157 research originates almost entirely from the Sikiric laboratory at the University of Zagreb, which has published hundreds of papers spanning multiple tissue systems over roughly three decades. No other research peptide of comparable duration has such a concentrated literature origin — which is both its strength and a factor worth understanding.

The research-grade compound is available as [BPC-157 10mg](/products/bpc-157-10mg).

## Structure: A Pentadecapeptide From Gastric Juice

BPC-157 is a 15-amino-acid fragment isolated from a larger gastric protective protein in human gastric juice. The synthetic pentadecapeptide reproduces this sequence and shows stability in gastric fluid — an unusual property for a research peptide and the reason oral delivery has been studied at all.

## Key Mechanistic Findings

1. **Nitric oxide system engagement:** Interaction with endothelial nitric oxide synthase, modulating vascular responses
2. **VEGFR2 signaling:** Involvement in angiogenic tissue repair — forming new vasculature during wound healing research
3. **Growth hormone receptor upregulation:** Secondary effect that may support the compound's broader repair profile
4. **Dopaminergic and serotonergic modulation:** CNS effects studied in the Sikiric inflammation models

## Tissue Systems Studied

The Sikiric literature spans:

- **GI mucosa** — the originally published system
- **Tendon and ligament** — rat Achilles transection research
- **Bone** — fracture healing studies
- **Skin** — wound closure models
- **CNS** — neuroprotection research in stroke models
- **Cardiovascular** — endothelial response studies

The breadth is notable — and is the reason BPC-157 shows up in so many adjunct-research contexts.

## Oral vs Subcutaneous Delivery Research

BPC-157's gastric stability has enabled oral research protocols — unusual for a peptide. The comparative literature suggests the subcutaneous route produces more predictable systemic exposure; the oral route produces effects more concentrated in the GI system. Research design should select based on the target tissue.

## Pairing With Other Research Compounds

BPC-157 is frequently paired with TB-500 in broader tissue-repair protocols. The mechanisms are non-overlapping — BPC-157 engages the NO and VEGFR2 systems while TB-500 targets G-actin dynamics and has its own VEGF interactions — so co-study covers a wider repair pathway set.

## Research Sourcing

Quality controls that matter for BPC-157 specifically: >98% HPLC purity, third-party test reports, lyophilized form, and stability-validated handling. See [BPC-157 10mg](/products/bpc-157-10mg) for the standard research vial.
    `.trim(),
  },
  {
    slug: 'ghk-cu-research-guide',
    title: 'GHK-Cu: The Copper Tripeptide Research Compound',
    seoTitle: 'GHK-Cu Research Guide — Copper Peptide, Gene Expression, Collagen',
    seoDescription:
      'GHK-Cu explained: the copper tripeptide structure, gene expression research across 4,000+ targets, collagen and elastin pathways, and topical research protocols.',
    date: '2026-04-03',
    excerpt:
      'GHK-Cu is one of the most studied copper peptides — three amino acids, one copper ion, and a surprisingly broad gene expression profile. Here is the research picture.',
    readTime: '8 min',
    body: `
## Three Amino Acids and One Copper Ion

GHK-Cu (glycyl-histidyl-lysyl-copper) is a tripeptide-copper complex. The copper ion coordinates with the imidazole of histidine and the amino terminus of glycine — the resulting complex is the biologically active species.

The research-grade compound is available as [GHK-Cu 50mg](/products/ghk-cu-50mg) for topical and injectable research.

## Gene Expression Research at Scale

The most striking characteristic of GHK-Cu is the breadth of its transcriptomic footprint. Published microarray data shows modulation across approximately 4,000 human genes — upregulating roughly one-third and downregulating another third from baseline.

Key upregulated gene families:

- **Collagen types I, III, IV** — dermal matrix proteins
- **Elastin and fibrillin** — dermal elasticity architecture
- **Decorin** — collagen fiber organization
- **Glycosaminoglycan synthesis enzymes** — hyaluronic acid and related GAGs

Key downregulated:

- **Matrix metalloproteinases (MMP-1, MMP-3)** — collagen-degrading enzymes
- **TGF-β1 inhibitory pathways** under some conditions

## Dermal Matrix Research Implications

The gene expression data translates to a research picture where GHK-Cu supports collagen synthesis while suppressing collagen degradation — a net positive shift in matrix turnover. The integrated research literature spans:

- Dermal thickness studies
- Wound closure kinetics
- Photoaging response models
- Hair follicle research — a secondary but actively studied application

## Topical vs Injectable Research

Both routes have their own literature:

- **Topical:** Most cosmetic research uses aqueous or serum formulations. Penetration depends on formulation vehicle and skin condition.
- **Injectable:** Subcutaneous or intradermal — produces more consistent systemic exposure and bypasses skin barrier variables.

Research design should select based on the target tissue depth and the variables to control.

## Pairing With Other Cosmetic Peptides

GHK-Cu pairs cleanly with SNAP-8 in cosmetic research stacks — the two compounds target entirely different mechanisms (gene expression vs SNARE complex inhibition), so no mechanism overlap occurs.

## Sourcing Research-Grade GHK-Cu

Copper peptide purity is particularly important because the copper coordination is the active form. Third-party HPLC certification should confirm both peptide purity and copper content. Browse [GHK-Cu 50mg](/products/ghk-cu-50mg) for the standard research vial.
    `.trim(),
  },
  {
    slug: 'snap-8-research-guide',
    title: 'SNAP-8: SNARE Complex Research Peptide',
    seoTitle: 'SNAP-8 Research Guide — Acetyl Octapeptide-3, SNARE Complex, Topical Use',
    seoDescription:
      'SNAP-8 (Acetyl Octapeptide-3) research overview: SNARE complex competitive inhibition, expression line research, and topical formulation considerations.',
    date: '2026-04-05',
    excerpt:
      'SNAP-8 targets the same SNARE complex that botulinum toxin acts on — through a completely different mechanism. A look at the octapeptide and its research.',
    readTime: '7 min',
    body: `
## A Mechanistic Cousin to Botulinum — Without Being a Toxin

SNAP-8 (acetyl octapeptide-3) and botulinum toxin converge on the same cellular target — the SNARE complex at the neuromuscular junction — through fundamentally different mechanisms. Botulinum cleaves SNARE proteins enzymatically. SNAP-8 competes for SNARE assembly without proteolysis. That mechanistic difference is the reason SNAP-8 exists as a research peptide at all.

The compound is available as [SNAP-8 10mg](/products/snap-8-10mg) for topical research protocols.

## Structure: Acetyl Octapeptide-3

SNAP-8 is an eight-amino-acid N-terminal acetylated peptide patterned on a portion of the SNAP-25 protein — one of the three core SNARE complex components. The acetylation improves stability; the sequence provides the competitive binding motif.

## The SNARE Complex Research Context

At the neuromuscular junction, acetylcholine release requires the SNARE complex — a three-protein assembly (SNAP-25, syntaxin, synaptobrevin) that mediates synaptic vesicle fusion. The SNARE complex is the final common pathway for essentially all regulated neurotransmitter release.

SNAP-8 research suggests the peptide:

1. Competes with endogenous SNAP-25 for complex assembly
2. Reduces SNARE complex formation efficiency
3. Produces a dose-dependent reduction in acetylcholine release at the NMJ

The result is a research compound that modulates muscular contraction without the proteolytic mechanism of botulinum.

## Why Expression Lines Are Receptor-Level

Expression lines are formed in part by repeated contraction of facial mimetic muscles. The muscle contraction is driven by acetylcholine release at the NMJ. Research that modulates acetylcholine release therefore modulates the upstream driver of expression line formation — which is why SNAP-8 research is typically framed in cosmetic contexts.

## Topical Formulation Research

Most SNAP-8 research is topical. Key formulation variables:

- **Vehicle:** aqueous serums, cream bases, or delivery-enhanced systems
- **Concentration:** varies widely in the published literature
- **Application frequency:** dose-response research is ongoing

Injectable research exists but is less common — the topical route matches the typical target (facial mimetic muscles) better.

## Pairing With Other Cosmetic Compounds

SNAP-8 pairs cleanly with GHK-Cu — NMJ-level mechanism vs gene-expression mechanism. Non-overlapping pathways cover the cosmetic research space more broadly than either compound alone.

## Sourcing

SNAP-8 research requires standard peptide QA: >98% HPLC purity, test reports, lyophilized form. See [SNAP-8 10mg](/products/snap-8-10mg) for the standard research vial.
    `.trim(),
  },
  {
    slug: 'cjc-1295-ipamorelin-research-guide',
    title: 'CJC-1295 + Ipamorelin: The GH Pulse Stack',
    seoTitle: 'CJC-1295 + Ipamorelin Research Guide — GHRH-R + Ghrelin Receptor Stack',
    seoDescription:
      'CJC-1295 and Ipamorelin research stack: GHRH-R amplitude + GHS-R1a pulsatility, non-overlapping mechanism, and GH axis research design.',
    date: '2026-04-07',
    excerpt:
      'CJC-1295 and Ipamorelin engage the GH axis through two different receptors. Here is why they are almost always studied together rather than alone.',
    readTime: '8 min',
    body: `
## Two Receptors, One Stack

The CJC-1295 + Ipamorelin stack is the most-studied GH axis research pair because it engages two orthogonal receptors simultaneously — amplifying GH pulse amplitude (CJC-1295) while preserving or enhancing pulsatility (Ipamorelin).

Both compounds ship together as [CJC-1295 + Ipamorelin](/products/cjc1295-ipamorelin) for paired research protocols.

## CJC-1295: GHRH Receptor Research

CJC-1295 is a modified GHRH analog. The modifications relevant to research:

- **Drug Affinity Complex (DAC) form:** Binds albumin for extended half-life (~8 days)
- **No-DAC form:** Native half-life (~30 minutes), pulsatile kinetics
- **Mechanism:** Binds the GHRH receptor on anterior pituitary somatotrophs, increasing GH release

The choice between DAC and no-DAC forms is the primary research design decision — DAC produces sustained elevation; no-DAC preserves natural pulse rhythm.

## Ipamorelin: Ghrelin Receptor Research

Ipamorelin is a selective GHS-R1a (ghrelin receptor) agonist. What makes it research-relevant:

- **Selectivity:** Binds GHS-R1a without meaningful engagement of other ghrelin-sensitive receptors
- **Lack of cortisol or prolactin elevation** — unlike earlier GHS-R agonists
- **Short half-life (~2 hours):** Enables pulsatile protocol design

The selectivity matters because first-generation ghrelin receptor compounds produced off-target endocrine effects that confounded GH-axis research.

## Why Pulsatility Matters More Than Amplitude

GH secretion is inherently pulsatile — and the downstream IGF-1 response depends on pulse architecture, not just cumulative GH concentration. Research that flattens the pulse pattern (through sustained GH elevation) produces a different IGF-1 and receptor-desensitization profile than research that preserves pulsatility.

This is the reason most research uses no-DAC CJC-1295 with Ipamorelin — both compounds have half-lives compatible with pulsatile dosing rhythm.

## Research Outcomes to Track

- **GH pulse amplitude and frequency**
- **IGF-1 levels** — the downstream integrated readout
- **IGFBP-3** — the primary IGF-1 binding protein
- **Secondary markers:** fat-free mass, recovery kinetics, sleep architecture

## Timing and Cadence

The most-studied protocol is twice- or thrice-daily dosing separated by at least 3–4 hours — spacing that respects pulse biology and avoids receptor desensitization.

## Sourcing the Paired Stack

Since the two compounds are nearly always studied together, a pre-paired format simplifies protocol logistics. See [CJC-1295 + Ipamorelin](/products/cjc1295-ipamorelin) for the paired research vial.
    `.trim(),
  },
  {
    slug: 'igf-1-lr3-research-guide',
    title: 'IGF-1 LR3: The IGFBP-Resistant Research Analog',
    seoTitle: 'IGF-1 LR3 Research Guide — LR3 Modification, IGFBP Resistance, IGF-1R',
    seoDescription:
      'IGF-1 LR3 research: the Long R3 modification, IGFBP resistance mechanism, IGF-1R downstream cascade, and research protocol windows.',
    date: '2026-04-09',
    excerpt:
      'IGF-1 LR3 solves the native IGF-1 binding problem through a 13-amino-acid N-terminal extension. Here is why that matters for research.',
    readTime: '7 min',
    body: `
## The Binding Problem LR3 Solves

Native IGF-1 in circulation is approximately 99% bound to IGFBPs (IGF binding proteins). Free IGF-1 is what reaches and activates the IGF-1 receptor — which means the IGFBPs act as a buffer that damps signal amplitude. Research on IGF-1 pharmacology has to account for this buffer or bypass it.

The LR3 modification bypasses it. The research-grade compound is available as [IGF-1 LR3 1mg](/products/igf-1lr3-1mg).

## The Long R3 Modification

IGF-1 LR3 carries two modifications vs native IGF-1:

1. **13-amino-acid N-terminal extension** — disrupts IGFBP binding
2. **Arg³ substitution** — further reduces IGFBP-3 affinity

The net result is a compound that maintains IGF-1R affinity while reducing IGFBP binding by orders of magnitude. More of the dosed compound reaches the receptor.

## Downstream IGF-1R Cascade

IGF-1R is a tyrosine kinase receptor. Activation initiates two primary signaling branches:

- **PI3K/Akt:** Protein synthesis, survival signaling, glucose uptake
- **MAPK/Ras:** Cell proliferation, gene expression modulation

The research-relevant outcome markers are:

- Ribosomal S6 kinase activation (protein synthesis)
- GLUT4 translocation (glucose handling)
- Myogenic differentiation markers

## Practical Implications for Research Protocols

- **Half-life ~20–30 hours** — longer than native IGF-1 but shorter than albumin-bound compounds
- **Systemic vs local:** Systemic dosing engages IGF-1R everywhere; site-specific research reduces systemic exposure
- **Receptor desensitization:** Sustained activation can downregulate IGF-1R — cycling is a research design consideration

## Research Context: The GH Axis

IGF-1 LR3 research sits downstream of GH axis research. A complete GH axis protocol typically engages:

1. **Upstream:** CJC-1295 or Sermorelin (GHRH receptor)
2. **Middle:** Ipamorelin or similar (ghrelin receptor / GH secretagogue)
3. **Downstream:** IGF-1 LR3 (IGF-1R direct activation)

Isolating the IGF-1R contribution requires studying LR3 alone; isolating upstream GH biology requires studying CJC/Ipamorelin alone. Combined research asks how the axis behaves under full activation.

## Sourcing IGF-1 LR3

Research-grade IGF-1 LR3 requires higher QC standards than many smaller peptides because folding and disulfide bond integrity are critical to IGF-1R affinity. >98% HPLC purity and mass spec verification are the standard. See [IGF-1 LR3 1mg](/products/igf-1lr3-1mg) for the research-grade vial.
    `.trim(),
  },
  {
    slug: 'tb-500-research-guide',
    title: 'TB-500: Thymosin Beta-4 Fragment Research',
    seoTitle: 'TB-500 Research Guide — Thymosin Beta-4, G-Actin Binding, VEGF',
    seoDescription:
      'TB-500 research overview: synthetic fragment of thymosin beta-4, G-actin binding mechanism, VEGF and NF-κB interactions, and tissue-repair research.',
    date: '2026-04-11',
    excerpt:
      'TB-500 is a synthetic fragment of thymosin beta-4 with a specific role in actin dynamics. The research profile spans multiple tissue systems.',
    readTime: '8 min',
    body: `
## Thymosin Beta-4 and Its Fragment

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein present in essentially every cell in mammalian tissue. It is the most abundant G-actin sequestering protein in most cell types — a structural role that underlies much of its downstream effect profile.

TB-500 is a synthetic fragment corresponding to the active region of Tβ4 — reproducing the core functional domain without the full-length protein. The research-grade compound is available as [TB-500 10mg](/products/tb-500-10mg).

## G-Actin Binding — The Structural Mechanism

G-actin is monomeric actin — the subunit that polymerizes into F-actin filaments. Cells maintain a reservoir of free G-actin that feeds polymerization during cytoskeletal remodeling. Tβ4 and TB-500:

1. Bind G-actin in a 1:1 complex
2. Sequester the monomer, buffering the free G-actin pool
3. Modulate the rate of actin polymerization and depolymerization
4. Indirectly influence cell migration, wound closure, and tissue remodeling

The mechanism is structural rather than receptor-mediated — a meaningful distinction for research design.

## VEGF and NF-κB Interactions

Beyond actin dynamics, the published literature identifies additional interactions:

- **VEGF pathway engagement** — angiogenesis during tissue repair
- **NF-κB modulation** — inflammatory signaling regulation
- **Stem cell migration** — particularly cardiac and dermal progenitors
- **MMP-2 and MMP-9 regulation** — extracellular matrix remodeling

The multi-pathway profile is why TB-500 research appears in such diverse tissue-repair contexts.

## Tissue Systems Researched

- **Cardiac:** Post-infarct tissue remodeling models
- **Dermal:** Wound closure and scar formation research
- **Tendon and ligament:** Injury-repair protocols
- **Corneal:** Epithelial wound healing
- **Neural:** Neuroprotection research

## Half-Life and Protocol Design

TB-500 has a relatively long duration of action for a research peptide — the sustained G-actin binding and downstream signaling effects extend beyond plasma clearance. Most protocols dose 1–2× per week.

## Pairing in Repair Stacks

TB-500 and BPC-157 are commonly paired. Mechanistically:

- **TB-500:** G-actin dynamics + VEGF/NF-κB modulation
- **BPC-157:** NO system + VEGFR2 + growth hormone receptor upregulation

The overlap at VEGF level is complementary rather than redundant — one engages upstream VEGF signaling, the other engages the VEGFR2 receptor directly.

## Sourcing

TB-500 research requires standard QA — >98% HPLC, third-party testing. The synthetic fragment should match the published Tβ4 active region sequence. See [TB-500 10mg](/products/tb-500-10mg) for the standard research vial.
    `.trim(),
  },
  {
    slug: 'epithalon-research-guide',
    title: 'Epithalon: Telomere-Associated Longevity Research',
    seoTitle: 'Epithalon Research Guide — Telomerase, Khavinson Literature, Longevity',
    seoDescription:
      'Epithalon research: the Khavinson laboratory literature, telomerase activation, pineal gland context, and modern longevity research protocols.',
    date: '2026-04-14',
    excerpt:
      'Epithalon is the most studied compound to emerge from the Khavinson laboratory. A look at the telomerase research, the pineal context, and how modern protocols frame it.',
    readTime: '9 min',
    body: `
## The Khavinson Peptide Tradition

Epithalon research originates from Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson's broader research program produced a family of short bioregulator peptides derived from organ extracts — Epithalon is the best-known of these, derived from bovine pineal extracts.

The research-grade synthetic peptide is available as [Epithalon 50mg](/products/epithalon-50mg).

## Sequence: A Tetrapeptide

Epithalon is a four-amino-acid sequence (Ala-Glu-Asp-Gly). At 390 Da molecular weight, it is one of the smallest research peptides — small enough that oral administration has been studied, though parenteral routes dominate the research literature.

## Telomerase Activation Research

The Khavinson literature reports that Epithalon induces telomerase activity in somatic cells — a property not shared by most short peptides. The proposed mechanism involves chromatin-level gene expression modulation rather than direct telomerase enzyme binding.

Published research outcomes:

- Telomerase activity increase in hematopoietic and somatic cells
- Telomere length changes over extended study windows
- Extension of cellular replicative lifespan in culture
- Modulation of aging-associated gene expression

The telomerase claim is the most cited and the most debated — modern replication studies outside the Khavinson group are limited, which is worth understanding when positioning Epithalon in a research protocol.

## Pineal Gland Context

The pineal extract origin is not incidental. The Khavinson group framed Epithalon research specifically around pineal-associated aging — melatonin rhythm, circadian regulation, and endocrine aging markers. This framing situates Epithalon in a broader neuroendocrine research context rather than as a purely telomerase-focused compound.

## Russian Literature and Translation

A significant portion of the Epithalon research literature is Russian-language and dates to the 1990s–2000s Khavinson era. Modern English-language research has built on this foundation but is not as voluminous. Researchers working with Epithalon benefit from awareness of both literature streams.

## Modern Research Protocols

Typical modern research protocols involve:

1. **Daily or every-other-day subcutaneous dosing**
2. **Cycled windows** — 10–20 day intensive periods separated by washout intervals
3. **Outcome markers:** telomerase activity assays, telomere length measurement (qPCR-based), aging-associated transcript panels

The cycled rhythm reflects the Khavinson-era protocols more than any pharmacokinetic constraint — Epithalon has a short plasma half-life.

## Research Handling

Standard lyophilized peptide handling applies: −20°C long-term storage, 2–8°C after reconstitution, 28-day reconstituted use window. Purity should be >98% HPLC verified. See [Epithalon 50mg](/products/epithalon-50mg) for the research-grade vial.
    `.trim(),
  },
  {
    slug: 'hgh-fragment-176-191-research-guide',
    title: 'HGH Fragment 176-191: Lipolytic Research Peptide',
    seoTitle: 'HGH Fragment 176-191 Research Guide — Lipolytic Activity Without IGF-1',
    seoDescription:
      'HGH Fragment 176-191 research overview: C-terminal GH fragment, lipolytic mechanism, why it avoids IGF-1 and glucose effects, and protocol positioning.',
    date: '2026-04-16',
    excerpt:
      'The C-terminal fragment of human growth hormone retains lipolytic activity without the full GH effects on IGF-1 or insulin. Here is why researchers care.',
    readTime: '7 min',
    body: `
## Isolating One Function From a Multi-Function Hormone

Full-length human growth hormone produces multiple overlapping effects: lipolysis, IGF-1 induction, insulin resistance, cellular proliferation. Research that wants to study one of these effects in isolation has to either use antagonists or use a fragment that retains only the target function.

HGH Fragment 176-191 is the second approach. The research-grade peptide is available as [HGH Fragment 176-191 5mg](/products/hgh-frag-176-191-5mg).

## The C-Terminal Region

Human growth hormone is a 191-amino-acid protein. Structure-function research has mapped different regions to different effects:

- **N-terminal / residues 1-15:** Insulin antagonism and glucose metabolism effects
- **Middle region:** IGF-1 induction via hepatic GH receptor activation
- **C-terminal / residues 177-191:** Lipolytic activity on adipose tissue

The 176-191 fragment captures the lipolytic region without the segments driving IGF-1 or glucose effects.

## Lipolytic Mechanism

The fragment's mechanism involves:

- **Beta-3 adrenergic activation** in adipose tissue
- **Hormone-sensitive lipase upregulation**
- **Triglyceride hydrolysis and fatty acid release**
- **Reduced lipogenesis** via inhibition of acetyl-CoA carboxylase

The net effect is accelerated fatty acid mobilization without the systemic metabolic effects of full GH.

## Why This Matters for Research Design

In full-GH research, teasing apart lipolysis vs IGF-1 vs insulin effects is difficult because all three occur simultaneously. The fragment approach asks: what happens when only the lipolytic axis is engaged?

This enables:

- Lipolysis dose-response studies without IGF-1 confounding
- Adipose-specific research without systemic growth effects
- Comparative research against full-length GH compounds

## Handling Notes

Lyophilized HGH Fragment is stable at −20°C long-term. Reconstitution with bacteriostatic water is standard. >98% HPLC purity is the research grade.

For research protocols targeting the lipolytic axis specifically, see [HGH Fragment 176-191 5mg](/products/hgh-frag-176-191-5mg).
    `.trim(),
  },
  {
    slug: 'mgf-research-guide',
    title: 'MGF: Mechano Growth Factor Research Overview',
    seoTitle: 'MGF Research Guide — IGF-1Ec Splice Variant & Muscle Satellite Cells',
    seoDescription:
      'MGF (Mechano Growth Factor) research background: IGF-1Ec splice variant, mechanical loading response, satellite cell activation, and site-specific protocols.',
    date: '2026-04-18',
    excerpt:
      'MGF is the IGF-1 splice variant muscle produces in response to mechanical loading. Here is why it operates on a different research timescale than standard IGF-1.',
    readTime: '8 min',
    body: `
## A Splice Variant, Not a Separate Gene

MGF (Mechano Growth Factor) is not a distinct gene product — it is the IGF-1Ec alternatively spliced variant of the IGF-1 gene, expressed preferentially by skeletal muscle in response to mechanical stress. Understanding MGF research requires understanding what distinguishes it from systemic IGF-1.

The research-grade peptide is available as [MGF 2mg](/products/mgf-2mg).

## The Mechanical Loading Response

When skeletal muscle experiences mechanical loading, the IGF-1 gene undergoes alternative splicing that produces the IGF-1Ec (MGF) transcript. The protein product:

- Has a 24-amino-acid C-terminal E-peptide extension
- Acts locally at the site of production
- Has a short half-life (minutes in circulation)
- Produces biological effects distinct from mature IGF-1

The localized, short-acting nature is the defining research property.

## Satellite Cell Activation

The primary MGF research target is the skeletal muscle satellite cell. MGF:

1. Activates dormant satellite cells
2. Promotes satellite cell proliferation
3. Delays myogenic differentiation (keeping cells in the proliferative pool longer)
4. Contributes to myofiber hypertrophy after injury or loading

The satellite cell pool is the regenerative reserve of skeletal muscle — research into its regulation is foundational to muscle biology.

## Native MGF vs PEG-MGF

Two research peptides exist for MGF studies:

- **Native MGF:** Short half-life, site-specific research
- **PEG-MGF:** Polyethylene glycol-modified, extended systemic half-life

The choice depends on the research question:

| Research Goal | Compound |
|---|---|
| Local satellite cell response | Native MGF |
| Systemic IGF-1Ec signaling | PEG-MGF |
| Site-of-injection pharmacology | Native MGF |
| Sustained circulating levels | PEG-MGF |

## Research Protocol Design

Native MGF's short half-life requires either:

- Frequent site-specific administration
- Acceptance that systemic effects are minimal
- Combined protocols with other GH-axis compounds

Combining native MGF with GH-releasing compounds (CJC/Ipamorelin) creates a research protocol that stimulates both systemic GH and local IGF-1Ec expression — a more complete GH-axis engagement.

## Sourcing

See [MGF 2mg](/products/mgf-2mg) for the standard research vial.
    `.trim(),
  },
  {
    slug: 'semax-research-guide',
    title: 'Semax: Russian Heptapeptide Research Overview',
    seoTitle: 'Semax Research Guide — ACTH(4-10) Fragment, BDNF, Nootropic Research',
    seoDescription:
      'Semax research: ACTH(4-10) heptapeptide structure, BDNF/NGF modulation, melanocortin receptor activity, and Russian neurological literature.',
    date: '2026-04-20',
    excerpt:
      'Semax is a synthetic ACTH fragment from Russian neurological research. A look at the sequence, the neurotrophic findings, and modern protocol use.',
    readTime: '7 min',
    body: `
## The ACTH Fragment Strategy

Adrenocorticotropic hormone (ACTH) is a 39-amino-acid pituitary hormone with two distinct functional regions: residues 1-24 handle the adrenal stimulation of cortisol release, and residues 4-10 carry neurotropic activity. Isolating the neurotropic region without the adrenal region was the research premise behind Semax.

The research-grade compound is available as [Semax 10mg](/products/semax-10mg).

## Sequence: ACTH(4-10) With Modifications

Semax is Met-Glu-His-Phe-Pro-Gly-Pro — a heptapeptide that:

1. Retains the ACTH(4-7) neurotropic core
2. Substitutes a terminal Pro-Gly-Pro for stability
3. Eliminates the adrenal-activating portion of the parent hormone
4. Gains resistance to peptidase cleavage

The result is a research compound that engages neurotropic ACTH effects without triggering cortisol release.

## Neurotrophic Factor Research

The most characterized Semax effects involve endogenous neurotrophic factor modulation:

- **BDNF (Brain-Derived Neurotrophic Factor):** Upregulation in hippocampal tissue
- **NGF (Nerve Growth Factor):** Increased expression in cortical regions
- **TrkB receptor signaling:** Downstream of BDNF effects

Elevating endogenous neurotrophic signaling is the proposed mechanism behind the cognitive and neuroprotective findings in the Russian literature.

## Melanocortin Receptor Interactions

Semax retains the histidine-phenylalanine core of ACTH(4-10) — the region responsible for melanocortin receptor binding. Research suggests modest MC4R activity, which contributes to:

- Cognitive enhancement observations
- Modulation of stress-axis signaling (paradoxically, given the ACTH origin)
- Interaction with dopaminergic systems

## Russian Research Context

Much of the foundational Semax literature is Russian-language, dating to the 1980s-1990s. The compound was developed at the Institute of Molecular Genetics and tested extensively in stroke recovery, cognitive enhancement, and optic nerve protection contexts. Western research builds on this foundation but is less extensive.

## Plain Semax vs N-Acetyl Semax Amidate

Two Semax research compounds exist:

- **Plain Semax:** Original heptapeptide, shorter half-life
- **N-Acetyl Semax Amidate (NA-Semax):** Modified for stability and intranasal delivery, longer duration

Plain Semax matches the original Russian protocols; NA-Semax is the modern optimized research form. Choice depends on whether the research replicates foundational work or extends it with improved pharmacokinetics.

See [Semax 10mg](/products/semax-10mg) for the standard research vial.
    `.trim(),
  },
  {
    slug: 'humanin-research-guide',
    title: 'Humanin: Mitochondrial-Derived Peptide Research',
    seoTitle: 'Humanin Research Guide — MDP, FPR2/gp130 Signaling, Neuroprotection',
    seoDescription:
      'Humanin research overview: 24-AA mitochondrial-derived peptide, FPR2 and gp130 receptor activity, neuroprotective mechanisms, and MDP family context.',
    date: '2026-04-22',
    excerpt:
      'Humanin was the first mitochondrial-derived peptide discovered — encoded inside the mitochondrial genome itself. A look at the signaling and the research landscape.',
    readTime: '8 min',
    body: `
## A Peptide Encoded Inside the Mitochondrial Genome

Humanin is unusual for a peptide: it is encoded within the 16S rRNA gene of mitochondrial DNA, not by the nuclear genome. Its discovery launched the "mitochondrial-derived peptide" (MDP) category — a small but growing family that now includes MOTS-c and the SHLPs (small humanin-like peptides).

The research-grade compound is available as [Humanin 10mg](/products/humanin-10mg).

## Structure: A 24-Amino-Acid Peptide

Humanin is a 24-amino-acid peptide. Analogs with modifications have been developed for improved stability — the most-studied is HNG (S14G humanin), though native humanin remains the reference research compound.

## Receptor Signaling: Two Pathway Branches

Humanin engages two distinct receptor systems:

1. **FPR2/FPRL1:** Formyl peptide receptor 2 — activates anti-apoptotic signaling
2. **CNTFR/WSX-1/gp130:** Heterotrimeric complex — activates STAT3 signaling

Both pathways converge on cellular survival and anti-apoptotic outcomes. This dual-receptor profile gives humanin broader biological reach than most single-receptor peptides.

## Research Domains

Four research areas dominate the humanin literature:

- **Neuroprotection:** Particularly against amyloid-beta toxicity in Alzheimer's models
- **Metabolic regulation:** Insulin sensitivity and glucose handling research
- **Cardioprotection:** Ischemia-reperfusion injury models
- **Cellular aging:** Reduced humanin levels correlate with aging markers

The breadth reflects both the dual-receptor signaling and the mitochondrial origin — mitochondrial health touches many aging-relevant pathways.

## The MDP Family Context

Since humanin's discovery, other MDPs have been identified:

| Peptide | Source | Primary Target |
|---|---|---|
| Humanin | 16S rRNA | FPR2, gp130 |
| MOTS-c | 12S rRNA | AMPK, folate cycle |
| SHLP-1 | 16S rRNA | Cellular metabolism |
| SHLP-2 | 16S rRNA | Neuroprotection |

Humanin and MOTS-c are the two best-characterized; the SHLPs are earlier-stage research.

## Handling

Lyophilized humanin is stable at −20°C. Reconstituted solutions at 2–8°C should be used within 28 days. >98% HPLC purity is the research standard.

For mitochondrial-derived peptide research, see [Humanin 10mg](/products/humanin-10mg).
    `.trim(),
  },
  {
    slug: 'liraglutide-research-guide',
    title: 'Liraglutide: The First-Generation GLP-1 Reference',
    seoTitle: 'Liraglutide Research Guide — C16 Fatty Acid, 13-Hour Half-Life, GLP-1R',
    seoDescription:
      'Liraglutide research: C16 fatty acid modification, 13-hour half-life, GLP-1R pharmacology, and positioning as the predecessor to semaglutide.',
    date: '2026-04-24',
    excerpt:
      'Liraglutide is the GLP-1 analog semaglutide iterated on. Understanding liraglutide clarifies why the C18 → C16 change mattered and how the class evolved.',
    readTime: '7 min',
    body: `
## Why First-Generation Compounds Still Matter in Research

Liraglutide was the first daily-dosed GLP-1 analog to enter clinical research, and much of the foundational GLP-1R pharmacology literature uses it rather than semaglutide. Comparative research between generations benefits from access to the reference compound.

The research-grade peptide is available as [Liraglutide 10mg](/products/liraglutide-10mg).

## The C16 Fatty Acid Modification

Native GLP-1 has a half-life of ~2 minutes. Liraglutide extends this to ~13 hours through a C16 palmitic acid side chain attached via a glutamic acid spacer. The palmitic acid binds circulating albumin:

- Shielding from DPP-IV cleavage
- Reducing renal clearance
- Enabling once-daily dosing

Semaglutide later extended this further with a C18 diacid — producing a 7-day half-life and once-weekly dosing.

## Sequence Homology

Liraglutide is 97% homologous with native human GLP-1 — a single amino acid substitution (Lys²⁶→Arg²⁶) plus the fatty acid attachment. The minimal sequence change preserves native-like receptor pharmacology while enabling the half-life extension.

Semaglutide carries additional modifications (Aib substitution at position 8, the extended C18 diacid) that further alter the pharmacokinetic profile.

## Research Positioning

Liraglutide earns research utility in specific contexts:

- **Daily-dosing research:** Where weekly kinetics would obscure dose-response
- **Acute pharmacology:** The shorter half-life allows cleaner PK studies
- **Historical comparison:** Matching the foundational GLP-1 clinical literature
- **Generational comparison:** Vs semaglutide for structure-activity research

## LEAD and SCALE Trial Context

The LEAD (Liraglutide Effect and Action in Diabetes) and SCALE (Satiety and Clinical Adiposity Liraglutide Evidence) trials produced the foundational clinical literature. Peak weight effect in SCALE: approximately −8% at 56 weeks at the 3.0mg dose — substantially less than semaglutide's STEP-1 result of −14.9%.

The delta between the two compounds is itself a research question: how much of the improvement comes from the longer half-life vs the sequence modifications?

## Handling

Standard lyophilized peptide handling — −20°C long-term, 2–8°C reconstituted, >98% HPLC purity.

For reference-compound GLP-1R research, see [Liraglutide 10mg](/products/liraglutide-10mg).
    `.trim(),
  },
  {
    slug: 'exenatide-research-guide',
    title: 'Exenatide: The Original GLP-1 Agonist Research Compound',
    seoTitle: 'Exenatide Research Guide — Exendin-4, DPP-IV Resistance, GLP-1R',
    seoDescription:
      'Exenatide (Exendin-4) research: Gila monster venom origin, DPP-IV resistance via N-terminal glycine, and foundational GLP-1R pharmacology.',
    date: '2026-04-26',
    excerpt:
      'Before liraglutide, before semaglutide, there was exenatide — a peptide isolated from Gila monster venom that opened the entire GLP-1 research field.',
    readTime: '7 min',
    body: `
## A Peptide From Lizard Venom

Exendin-4 was isolated from the saliva of the Gila monster (Heloderma suspectum) in the early 1990s. Its 53% sequence homology with mammalian GLP-1 and its resistance to DPP-IV cleavage made it the first viable GLP-1R agonist research compound — predating all the modified-analog approaches used in liraglutide and semaglutide.

Exenatide is the synthetic reproduction of exendin-4. The research-grade peptide is available as [Exenatide 5mg](/products/exenatide-5mg).

## Why DPP-IV Resistance Emerged Naturally

Mammalian GLP-1 is cleaved at the Ala²-Glu³ bond by dipeptidyl peptidase-IV — the reason native GLP-1 has a 2-minute half-life. Exendin-4 has a glycine at position 2 instead of alanine, blocking DPP-IV cleavage as a byproduct of evolutionary divergence in the Gila monster lineage.

The result: a peptide with inherent DPP-IV resistance, a 2-4 hour half-life, and GLP-1R agonist activity suitable for pharmacological research. No chemical modification was needed to achieve stability — the wild-type sequence already had it.

## Research Significance

Exenatide's research role has two angles:

1. **Historical:** The compound that validated GLP-1R agonism as a viable research and pharmacological target
2. **Contemporary:** A twice-daily-dosing compound distinct from the weekly-dosing modern analogs — useful for research where pulse architecture matters

## Comparative Pharmacology

| Compound | Half-Life | Dosing | Origin |
|---|---|---|---|
| Native GLP-1 | 2 min | — | Endogenous |
| Exenatide | 2-4 hr | BID | Gila monster sequence |
| Liraglutide | 13 hr | Daily | C16 fatty acid |
| Semaglutide | 7 days | Weekly | C18 diacid + Aib |

Exenatide occupies the short-acting position in the research lineup.

## Cellular Biology

Once bound to GLP-1R, exenatide and native GLP-1 produce indistinguishable downstream signaling: Gs coupling, adenylyl cyclase activation, cAMP elevation, PKA and EPAC2 activation. The receptor doesn't distinguish agonists based on origin — only affinity and duration.

This makes exenatide a clean research tool for studying GLP-1R pharmacology without the complications of fatty acid modifications that affect tissue distribution.

## Handling

Lyophilized exenatide is stable at −20°C. Reconstituted handling follows standard research peptide protocols.

For foundational GLP-1R research, see [Exenatide 5mg](/products/exenatide-5mg).
    `.trim(),
  },
  {
    slug: 'pramlintide-research-guide',
    title: 'Pramlintide: The Amylin Analog Research Peptide',
    seoTitle: 'Pramlintide Research Guide — Proline Substitutions, Amylin Receptor, CALCR/RAMP',
    seoDescription:
      'Pramlintide research: proline substitutions that prevent amyloidogenesis, amylin receptor pharmacology (CALCR/RAMP), and research vs cagrilintide.',
    date: '2026-04-28',
    excerpt:
      'Native human amylin forms fibrils — a pharmacology dead-end. Pramlintide solves the aggregation problem with three proline substitutions. Here is the story.',
    readTime: '8 min',
    body: `
## The Amyloidogenesis Problem

Human amylin (also called islet amyloid polypeptide, IAPP) has a problem: at concentrations above physiological levels, it forms amyloid fibrils. This is not a research inconvenience — amylin fibrils are the pathological finding in type 2 diabetic pancreatic tissue. Using native human amylin as a research peptide is nearly impossible because of aggregation during handling.

Pramlintide solves this through targeted amino acid substitutions. The research-grade peptide is available as [Pramlintide 5mg](/products/pramlintide-5mg).

## The Rat-Sequence Inspiration

Rat amylin does not form fibrils. Comparing rat and human amylin sequences reveals three key differences at positions 25, 28, and 29 — positions that happen to be in the aggregation-prone region of the peptide. In rat amylin, these positions are prolines; in human amylin, they are alanine and serines.

Pramlintide swaps the human residues for the rat prolines:

- **Position 25:** Ala → Pro
- **Position 28:** Ser → Pro
- **Position 29:** Ser → Pro

The substitutions disrupt the beta-sheet architecture required for fibril formation while preserving receptor binding.

## Amylin Receptor Pharmacology

Amylin receptors are not standalone GPCRs — they are heterodimeric complexes of the calcitonin receptor (CALCR) with receptor activity-modifying proteins (RAMPs):

- **AMY1 receptor:** CALCR + RAMP1
- **AMY2 receptor:** CALCR + RAMP2
- **AMY3 receptor:** CALCR + RAMP3

Pramlintide binds all three complexes. Downstream signaling includes:

- **Gastric emptying delay** — slowing nutrient delivery
- **Glucagon suppression** — reducing hepatic glucose output
- **Appetite suppression** — hypothalamic action

## Pramlintide vs Cagrilintide in Research

Both target amylin receptors:

| Property | Pramlintide | Cagrilintide |
|---|---|---|
| Half-life | 48 min | ~7 days |
| Dosing | Mealtime (TID) | Weekly |
| Modification | Proline substitutions | C20 fatty acid + substitutions |
| Research role | Acute pharmacology | Long-acting protocol research |

The short half-life of pramlintide makes it suitable for mealtime-aligned research and acute dose-response studies. Cagrilintide is the long-acting research tool for sustained amylin receptor engagement.

## Combined Research Context

Amylin receptor agonists are commonly studied alongside GLP-1R agonists because the pathways are non-overlapping — the CagriSema combination (cagrilintide + semaglutide) is the modern example. Pramlintide + short-acting GLP-1R research is the equivalent acute pharmacology setup.

## Handling

Standard lyophilized peptide handling applies. >98% HPLC purity. See [Pramlintide 5mg](/products/pramlintide-5mg) for the research vial.
    `.trim(),
  },
  {
    slug: 'kisspeptin-54-research-guide',
    title: 'Kisspeptin-54: HPG Axis Research Peptide',
    seoTitle: 'Kisspeptin-54 Research Guide — KISS1R Signaling & Reproductive Endocrine',
    seoDescription:
      'Kisspeptin-54 research: full-length kisspeptin structure, KISS1R (GPR54) signaling, GnRH upstream regulation, and HPG axis research protocols.',
    date: '2026-04-30',
    excerpt:
      'Kisspeptin is the upstream regulator of GnRH secretion — the gatekeeper of reproductive endocrine biology. A look at the 54-form and its research role.',
    readTime: '8 min',
    body: `
## The Gatekeeper of the Reproductive Axis

Before GnRH can initiate the LH/FSH cascade, hypothalamic GnRH neurons have to be activated. For decades, the upstream trigger for GnRH release was unclear. The 2003 discovery that kisspeptin and its receptor KISS1R (GPR54) are essential for pubertal onset — and that loss-of-function mutations in this system cause hypogonadotropic hypogonadism — established kisspeptin as the gatekeeper of the HPG axis.

The research-grade peptide is available as [Kisspeptin-54 10mg](/products/kisspeptin-54-10mg).

## Why Kisspeptin-54 Specifically

The KISS1 gene encodes a 145-amino-acid prohormone that is cleaved into several active products:

- **Kisspeptin-54:** Full-length circulating form
- **Kisspeptin-14:** Internal fragment
- **Kisspeptin-13:** Internal fragment
- **Kisspeptin-10:** C-terminal decapeptide, minimal active fragment

All four share the C-terminal RF-amide region required for KISS1R binding. Research differences:

| Form | Half-life | LH Response | Research Use |
|---|---|---|---|
| Kisspeptin-54 | Longer | Sustained | Physiological protocols |
| Kisspeptin-10 | Shorter | More acute | Dose-response pharmacology |

Kisspeptin-54 is closest to the native circulating form.

## KISS1R Signaling

KISS1R (also called GPR54) is a Gq-coupled GPCR expressed on hypothalamic GnRH neurons. Activation produces:

1. PLC activation and PIP2 hydrolysis
2. IP3-mediated calcium release
3. GnRH neuron depolarization
4. GnRH release into the median eminence
5. Downstream LH and FSH secretion from pituitary gonadotropes
6. Gonadal steroidogenesis via LH/FSH

The signaling is classical — what makes kisspeptin unique is the anatomical specificity to GnRH neurons.

## Research Domains

- **Puberty research:** KISS1R loss-of-function models
- **Reproductive endocrinology:** GnRH pulsatility regulation
- **Fertility research:** Ovulation induction pharmacology
- **Metabolic-reproductive coupling:** Leptin-kisspeptin integration

The metabolic-reproductive axis is a particularly active research area — kisspeptin appears to be one of the nodes where energy balance information reaches the HPG axis.

## Pulsatility Matters Here Too

Like GH, the HPG axis operates on pulsatile secretion. Continuous kisspeptin exposure eventually produces GnRH desensitization, while pulsatile exposure maintains responsiveness. Research protocols have to account for this when designing dosing rhythm.

## Handling

Standard lyophilized peptide handling — −20°C, 2–8°C reconstituted, >98% HPLC. See [Kisspeptin-54 10mg](/products/kisspeptin-54-10mg) for the research vial.
    `.trim(),
  },
  {
    slug: 'angiotensin-1-7-research-guide',
    title: 'Angiotensin(1-7): The Counter-Regulatory RAS Peptide',
    seoTitle: 'Angiotensin(1-7) Research Guide — Mas Receptor, ACE2 Axis, Cardioprotection',
    seoDescription:
      'Angiotensin(1-7) research: ACE2/Ang(1-7)/MasR counter-regulatory axis of the RAS, cardiovascular research, and anti-fibrotic mechanisms.',
    date: '2026-05-02',
    excerpt:
      'The renin-angiotensin system has two arms. Most of the textbook biology covers the vasoconstrictor arm. Angiotensin(1-7) is the counter-regulatory one — and it is its own research field.',
    readTime: '8 min',
    body: `
## Two Arms of a System Usually Taught as One

Most textbook teaching of the renin-angiotensin system (RAS) focuses on the ACE → Angiotensin II → AT1 receptor axis — vasoconstriction, aldosterone release, fluid retention, inflammation. What the textbook treatment often underemphasizes is that this axis has a parallel counter-regulatory arm: ACE2 → Angiotensin(1-7) → Mas receptor, which produces the opposite effects.

The research-grade peptide is available as [Angiotensin(1-7) 10mg](/products/angiotensin-1-7-10mg).

## ACE2: The Counter-Regulatory Enzyme

ACE2 (angiotensin-converting enzyme 2) shares ~40% homology with ACE but produces different products. Where ACE generates angiotensin II (vasoconstrictor), ACE2 cleaves angiotensin II into angiotensin(1-7) — converting the bad-arm mediator into the good-arm mediator.

The same enzyme balance:

- High ACE activity → Ang II accumulation → AT1R activation → vasoconstriction, inflammation
- High ACE2 activity → Ang(1-7) accumulation → MasR activation → vasodilation, anti-inflammation

## The Mas Receptor

Mas (MAS1) is a GPCR with high specificity for Ang(1-7). Signaling includes:

1. **Vasodilation** via NO release and prostaglandin signaling
2. **Anti-fibrotic effects** through TGF-β pathway modulation
3. **Anti-proliferative signaling** via MAPK pathway downregulation
4. **Anti-inflammatory effects** on immune cells

Each effect is the opposite of what AT1R activation produces — hence "counter-regulatory."

## Research Domains

Angiotensin(1-7) research spans:

- **Cardiovascular:** Hypertension models, cardiac remodeling research
- **Renal:** Anti-fibrotic kidney research
- **Pulmonary:** ACE2/Ang(1-7) axis in lung injury models (heavily studied post-2020)
- **Metabolic:** Insulin sensitivity and adipose research
- **Oncology:** Anti-proliferative research in certain tumor models

## The Short Half-Life Challenge

Angiotensin(1-7) has a short plasma half-life (~30 seconds) in vivo due to rapid peptidase cleavage. Research protocols address this through:

- **Continuous infusion** in acute pharmacology studies
- **Oral cyclodextrin formulations** that extend exposure
- **Analog development** with peptidase resistance

Most research-grade Ang(1-7) work uses acute protocols that tolerate the short duration — the half-life is a research variable rather than a blocker.

## Pairing With Repair Compounds

Angiotensin(1-7) pairs cleanly with other repair-oriented research peptides (BPC-157, TB-500) because the anti-fibrotic and vasodilatory mechanisms are non-overlapping with NO/VEGF or actin-dynamics pathways.

## Handling

Standard lyophilized peptide handling — −20°C, bacteriostatic water reconstitution, >98% HPLC purity. See [Angiotensin(1-7) 10mg](/products/angiotensin-1-7-10mg) for the research vial.
    `.trim(),
  },
  {
    slug: 'orexin-a-research-guide',
    title: 'Orexin-A: Hypocretin System Research Peptide',
    seoTitle: 'Orexin-A Research Guide — OX1R/OX2R, Hypocretin-1, Wake Regulation',
    seoDescription:
      'Orexin-A research: 33-AA lateral hypothalamus neuropeptide, OX1R/OX2R signaling, wakefulness regulation, and narcolepsy/sleep research.',
    date: '2026-05-04',
    excerpt:
      'Orexin-A is the wakefulness-driving neuropeptide whose absence causes narcolepsy. A look at the hypocretin system and its research applications.',
    readTime: '7 min',
    body: `
## The Peptide Whose Absence Defines a Disease

Narcolepsy with cataplexy — the classic autoimmune-mediated narcolepsy — is characterized by loss of orexin-producing neurons in the lateral hypothalamus. The absence of orexin signaling is literally the disease. This makes orexin-A one of the rare research peptides with a definitive clinical correlate for its loss-of-function state.

The research-grade peptide is available as [Orexin-A 5mg](/products/orexin-a-5mg).

## Two Discoveries, Two Names

Orexin-A and Hypocretin-1 are the same peptide. In 1998, two research groups independently discovered the compound and published nearly simultaneously:

- **Sakurai et al.:** Named it "orexin" (Greek *orexis*, appetite) based on initial feeding-behavior observations
- **de Lecea et al.:** Named it "hypocretin" (hypothalamic + secretin-like) based on sequence homology

Both names persist in the literature. Orexin is more common in metabolic and pharmacological research; hypocretin dominates sleep biology.

## Structure: A 33-Amino-Acid Peptide

Orexin-A has two intrachain disulfide bonds and N-terminal pyroglutamation — modifications that contribute to its stability and receptor affinity. It is produced from the preproorexin precursor alongside orexin-B (28 AA), though the two peptides have somewhat different receptor preferences.

## Receptor Pharmacology

The orexin system has two GPCR receptors:

| Receptor | Affinity for Orexin-A | Affinity for Orexin-B |
|---|---|---|
| OX1R (HCRTR1) | High | Lower (~10× less) |
| OX2R (HCRTR2) | High | High |

Orexin-A binds both receptors with similar affinity — making it the "pan-orexin" research tool compared to orexin-B's OX2R preference.

## Primary Research Functions

**Wakefulness and arousal:**
Orexin neurons in the lateral hypothalamus project widely — to monoaminergic nuclei (locus coeruleus, raphe, ventral tegmental area) and to the basal forebrain cholinergic system. Activation of these targets maintains cortical arousal.

**Feeding and energy balance:**
Orexin neurons sense glucose and leptin signals, producing integrated output that couples feeding drive to arousal state.

**Reward and motivation:**
OX1R signaling in the VTA modulates dopaminergic reward pathways, linking the orexin system to motivation research.

## Research Applications

- **Sleep biology:** Narcolepsy models, circadian research
- **Neuropharmacology:** Dual orexin receptor antagonists (DORAs) are a major drug development area; research agonists provide the reverse pharmacology
- **Metabolic research:** Feeding-arousal integration
- **Addiction research:** OX1R role in drug-seeking behavior

## Handling

Lyophilized orexin-A requires careful handling — the disulfide bonds are sensitive to reducing conditions. Standard bacteriostatic water reconstitution is appropriate; avoid DTT or mercaptoethanol-containing buffers. >98% HPLC purity is the research standard.

See [Orexin-A 5mg](/products/orexin-a-5mg) for the research vial.
    `.trim(),
  },
]

export function getAllGuideSlugs() {
  return guides.map((g) => g.slug)
}

export function getGuideBySlug(slug: string): Guide | undefined {
  return guides.find((g) => g.slug === slug)
}
